

PR#: 14551 Deviation No.:D-2021-0244

Record Status: Closed-Done

基本信息 General Information

□ Division: Innovent Biologics (Su Zhou) Co., Ltd

发起人 Originator: 王, 金祥(PID-000083) 发起日期 Date Opened: 2021.05.18

简短描述 Short Description:

M1b DS1亲和层析cycle1 UV检测用稀释溶液pH未调中性 The pH of the buffer for UV testing sample dilution is not neutralized in

DS2103015AC1

到期日期 Date Due: 2021.05.19 关闭日期 Date Closed: 2021.05.20

偏差信息 Deviation Information

偏差描述 Deviation Description:

2021.05.18 00:25纯化人员(20000502)在调节完离心管亲和洗脱液(DS2103015-S285-01)后,发现DS2103015AC1蛋白检测的洗脱液未进行pH调节;与《信迪利单抗注射液(二代细胞株)M1b 3000L原液纯化批生产记录》(文件编码/版本:BPR100468/02,批号:DS2103015)中1.6蛋白含量检测(3)中"用IBI308用IBI308 2nd 2 mol/L Tris Base将IBI308 2nd亲和洗脱液调节至pH6.0~8.0之间作为稀释液"的要求不符。故发起偏差。

描述的附件 Description attachment:

是否及时上报? Reporting in Time?: Yes

未及时上报的理由 Reason for not in Time:

N/A

已采取的即时措施 Immediately Action Taken:

05/18/2021 07:32 PM (GMT+8:00) added by 金祥 王 (PID-000083):

N/A

即时措施附件 Immediately Action Attachment:

厂房设施名称 Facility Name: 产品所属阶段 Product Phase:

M1b Clinical

初步影响/风险评估Initial Impact/Risk Assessment

产品影响评估 Product Impact Assessment:

本次偏差只涉及样品检测的背景溶液的pH调节,不涉及产品工艺生产;故对产品的质量无影响。

生产/检测的影响评估 Production/Testing Impact Assessment:

本次是DS2103015AC1蛋白含量检测,背景溶液为"100mM甘氨酸-盐酸,30mM氯化钠,pH3.50"。该溶液在工艺生产中为亲和洗脱液。根据《信迪利单抗注射液(二代细胞株)3000L原液纯化工艺规程》(PFD00173/03)对亲和收集液pH调节要求"由于亲和收集液pH较低,不利于保存",可知此pH较低的条件下抗体不稳定,会导致浓度检测结果不准确,因此需要重新检测(检测结果建立偏差行动项PR#14561)。目前AC1蛋白含量的结果已经重新引用执行完偏差行动项后的检测结果,因此对当前步骤的影响较小;其次,亲和cycle1收集液送QC检测纯度和残留的送样单样品浓度已更正(见附件1),因此对检测结果无影响;再次亲和cycle1收集液浓度不影响AC混合后的蛋白含量检测且cycle1收集液浓度不会用于后续的生产。综上,本偏差对后续生产和检测无影响。

其他影响评估描述 Other Impact Assessment Description:

本次偏差纯化人员未按照批生产记录的要求,确认完亲和洗脱液调节至pH6.0~8.0之间再进行使用,导致了偏差。《信迪利单抗注射液(二代细胞株)M1b 3000L原液纯化批生产记录》(文件编码/版本:BPR100468/02,批号:DS2103015)中1.6蛋白含量检测(3)中已经明确"用IBI308用IBI308 2nd 2 mol/L Tris Base将IBI308 2nd亲和洗脱液调节至pH6.0~8.0之间作为稀释液"要求,现



14551 PR#: Deviation No.:D-2021-0244

Record Status: Closed-Done

有流程无问题,能够有效指导后续生产。因此,由于人员疏忽导致操作错误是本次偏差发生的原因。截至目前类似蛋白含量检测已被执 行2年多,未发生类似事件,因此为一起人员操作失误的偶发性事件,暂不考虑制定相关CAPA。为了巩固人员对该操作的细节,现建立 偏差行(PR#14616),对操作人员进行线下培训。

初步影响评估附件 Initial Impact Assessment Attachment:

偏差分级 Deviation Classification

偏差严重性 Deviation Severity:

对产品SISPQ的影响:

本次偏差只涉及样品检测的背景溶液的pH调节,不涉及产品工艺生产;故对产品的质量无影响。

偏差发生率 Reoccurrence Probability of Deviation:

过去12个月该区域同类型缺陷会(关键词搜索: M1b DS1、亲和层析cycle1、 UV检测用稀释溶液pH未调中性)

未发现同类型缺陷。

偏差分级 Deviation Classification: Minor

分级的理由 Reason for Classification:

05/19/2021 05:16 PM (GMT+8:00) added by 育芳 刘 (PID-000093):

该偏差原因及影响明确,无需进行进一步的调查,

综上,该偏差定义为次要偏差。

是否需要调查? Investigation Required?: No

主调查人 Lead investigator:

不需要调查的理由 Reason for not Investigation: 该偏差原因及影响明确,无需进行进一步的调查。

调查总结&根本原因分析 Investigation & RCA

调查总结 Investigation Summary:

调查附件 Investigation Attachments:

根本原因分析 Root Cause Analysis:

本次偏差纯化人员未按照批生产记录的要求,确认完亲和洗脱液调节至pH6.0~8.0之间再进行使用,导致了偏差。

根本原因分析附件 Root Cause Analysis Attachment:

原因描述 Cause Description:

本次偏差纯化人员未按照批生产记录的要求,确认完亲和洗脱液调节至pH6.0~8.0之间再进行使用,导致了偏差。

原因分类 Cause Category 原因子分类 Cause Sub-Category 原因归属部门 Cause Department

M1b DS1 Others Others



PR#: 14551 Deviation No.:D-2021-0244

Record Status: Closed-Done

缺陷描述 Defect Description:

2021.05.18 00:25纯化人员(20000502)在调节完离心管亲和洗脱液(DS2103015-S285-01)后,发现DS2103015AC1蛋白检

测的洗脱液未进行pH调节;与《信迪利单抗注射液(二代细胞株)M1b3000L原液纯化批生产记录》(文件编码/版

本:BPR100468/02, 批号:DS2103015)中1.6蛋白含量检测(3)中 "用IBI308用IBI308 2nd 2 mol/L Tris Base将IBI308

2nd亲和洗脱液调节至pH6.0~8.0之间作为稀释液"的要求

缺陷类型分类 Defect Category

Production/Process

缺陷类型子分类 Defect Sub-Category

Operation

是否是重复偏差 Repeat Deviation?: N/A

判定重复偏差的原因 Justification for Repeat Deviation:

不涉及

重复偏差的原因描述 Reason of Repeat Deviation Description:

不涉及

相关的重复偏差 Repeat Deviation Records

PR# deviation#

简短描述 Short Description

Record Status

最终影响/风险评估 Final Impact/Risk Assessment

| 对产品 | 品质量的影响 | Impact c | on Produ | ıct Quality: |
|-----|--------|----------|----------|--------------|
|-----|--------|----------|----------|--------------|

对其他批次的影响 Impact on Other Batches:

对系统/设备的影响 Impact on System/Equipment:

对验证状态的影响 Impact on Validation State:

对产品注册的影响 Impact on Product Registration:

对法规符合性的影响 Impact on Regulation Compliance:

对稳定性的影响 Impact on Stability:

对其他方面的影响 Impact on Other Aspects:

受影响的部门 Impact Departments:

影响/风险评估附件 Impact/Risk Assessment Attachment:



PR#: 14551 Deviation No.:D-2021-0244

Record Status: Closed-Done

受影响的产品信息 Impacted Product Information

产品最终处置建议 Product Disposition Proposal:

产品名称 Product Name:

产品代码 Product Code 产品批号 Batch No.: 数量 Quantity 处理决定 Disposition

受影响的物料信息 Impacted Material Information

物料名称 Material Name:

受影响的溶液信息 Impacted Media/Buffer Information

溶液名称 Media/Buffer Name:

受影响的设备信息 Impacted Equipment Information

设备名称 Equipment Name: 设备代码 Equipment Code

偏差处理措施 Deviation Action Items

PR#: 14561

责任人 Assigned To: 王, 金祥(PID-000083)部门 Department:M1b DS1截止日期 Date Due:2021.05.19完成日期 Completed Date:2021.05.18确认人 Verified By:吴, 烜(PID-000235)确认日期 Verified On:2021.05.19

行动项详细描述 Action Description:

由于UV检测的背景溶液未进行pH调节,缓冲液pH较低,对亲和收集液的浓度检测有影响。故需要对DS2103015AC1样品重新

检测。

PR#: 14616

责任人 Assigned To: 王, 金祥(PID-000083)部门 Department:M1b DS1截止日期 Date Due: 2021.05.19完成日期 Completed Date: 2021.05.19确认人 Verified By: 吴, 烜(PID-000235)确认日期 Verified On: 2021.05.20



PR#: 14551 Deviation No.:D-2021-0244

Record Status: Closed-Done

行动项详细描述 Action Description:

对本次操作人员培训:强调蛋白检测过程中要注意确认背景溶液是否已经满足检测需求。

纠正信息 Correction Information

PR#:

截止日期 Date Due: 完成日期 Completed Date:

确认人 Verified By: 确认日期 Verified On:

行动项详细描述 Action Description:

纠正与预防措施 CAPA

PR#:

责任人 Assigned To: 部门 Department:

截止日期 Date Due:

行动项详细描述 Action Description:

附件 File Attachments

附件1更正后的送样单.pdf

关联记录 Reference Records

PR# Record Type 简短描述 Short Description Record Status

相关子记录 Related children

| PR# | Record Type Deviation Action Items | 简短描述 Short Description | Record Status |
|------------|---|---|----------------------|
| 14561 | | 重新检测亲和 cycle1蛋白含量 To re-test the | Closed-Done |
| 14616 | Deviation Action Items | AC1 pool concentration 人员操作培训 Personnel operation training | Closed-Done |



PR#: 14551 Deviation No.:D-2021-0244

Record Status: Closed-Done

| Record Status: Closed-Done | | | |
|---|----------------|--|------------------|
| Initial Approval | | | |
| QA Initial Review | | | |
| Area QA Initial Reviewed By: | 吴, 烜 | Area QA Initial Reviewed On: | 2021.05.18 19:46 |
| Classify Completed By: | 刘, 育芳 | Classify Completed On: | 2021.05.19 19:48 |
| Department Initial Review | | | |
| Department Leader 1 Reviewed By: | 康, 云 | Department Leader 1 Reviewed On: | 2021.05.19 19:55 |
| Department Leader 2 Reviewed By: | | Department Leader 2 Reviewed On: | |
| Department Leader 3 Reviewed By: | | Department Leader 3 Reviewed On: | |
| Department Leader 4 Reviewed By: | | Department Leader 4 Reviewed On: | |
| Department Leader 5 Reviewed By: | | Department Leader 5 Reviewed On: | |
| Area QA Leader Reviewed By: | 代, 圆圆 | Area QA Leader Reviewed On: | 2021.05.20 09:28 |
| Quality Initial Approval | | | |
| Quality Approver 1 Approved By: | 管, 国兴 | Quality Approver 1 Approved On: | 2021.05.20 10:54 |
| Quality Approver 2 Approved By: | | Quality Approver 2 Approved On: | |
| Quality Approver 3 Approved By: | | Quality Approver 3 Approved On: | |
| Final Approval | | | |
| QA Final Review | | | |
| | | | |
| QA Final Reviewed By: | | QA Final Reviewed On: | |
| QA Final Reviewed By: Investigator Final Review | | QA Final Reviewed On: | |
| - | | QA Final Reviewed On: QA Representative Reviewed On: | |
| Investigator Final Review | | | |
| Investigator Final Review QA Representative Reviewed By: | | QA Representative Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: | y: | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: | n: |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: | | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: | |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: | y: | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: | ո։ |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By: | y: y: | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: | n: n: |
| Investigator Final Review QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By: Department Leader 3 Final Approved By: | y: y: y: | QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 9 Reviewed On: | n: n: n: |

Quality Final Approval

Quality Approver 1 Final Approved By: Quality Approver 1 Final Approved On:

Quality Approver 2 Final Approved By: Quality Approver 2 Final Approved On:



PR#: 14551 Deviation No.:D-2021-0244

Record Status: Closed-Done

Quality Approver 3 Final Approved By: Quality Approver 3 Final Approved On:

Product Final Disposition

Disposition Proposed By:

Proposal Reviewed By:

Disposition Proposed On:

Proposal Reviewed On:

Product Disposition Approved By: Product Disposition Approved On: